Hospital
ST Vincents Medical Center INC
ST Vincents Medical Center INC was paid $12.67M by Medicaid between Jan 2018 and Dec 2024, across 238 billing codes. Its largest line is 99285, emergency room visit (most serious) — 20% of everything it billed.
33Billing provider infoST VINCENTS MEDICAL CENTER INC
JACKSONVILLE, FL 32204
JACKSONVILLE, FL 32204
33aNPI1134117575assigned 10/10/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$12.67M
24GClaims483,555
24DCodes billed238
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#40 of 163
Median peer was paid$4.77M
This provider vs. median2.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 56,060 | $490K | |
| 2019 | 106,937 | $2.50M | |
| 2020 | 87,419 | $2.19M | |
| 2021 | 102,986 | $2.93M | |
| 2022 | 98,537 | $3.21M | |
| 2023 | 27,418 | $1.09M | |
| 2024incomplete | 4,198 | $264K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 20% | 27,742 | 23,108 | $2.57M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.0% | 12,465 | 11,382 | $1.15M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.2% | 12,013 | 10,639 | $910K |
| 36415 | Collection of venous blood by venipuncture | 5.3% | 24,611 | 17,294 | $677K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 4.8% | 4,264 | 3,721 | $605K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.6% | 5,986 | 5,495 | $454K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.8% | 8,914 | 7,983 | $349K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.6% | 990 | 875 | $334K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2.5% | 6,159 | 5,105 | $316K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 2.3% | 1,460 | 1,248 | $291K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 2.2% | 754 | 705 | $281K |
| 80053 | Comprehensive metabolic panel | 2.1% | 19,243 | 15,456 | $261K |
226 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 4,993 | $209K |
| 59025 | Fetal non-stress test | 1.5% | 2,123 | $193K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 2,929 | $191K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.5% | 9,823 | $187K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.4% | 3,964 | $178K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.4% | 2,326 | $178K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 3,563 | $176K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.0% | 2,625 | $132K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,434 | $118K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,609 | $107K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,200 | $92K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,581 | $90K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,553 | $85K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,690 | $82K |
| G0378 | Hospital observation service, per hour | <1% | 9,542 | $82K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,688 | $73K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 624 | $73K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 81 | $73K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,803 | $66K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 923 | $65K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,396 | $64K |
| 71250 | <1% | 1,674 | $60K | |
| 76536 | <1% | 819 | $59K | |
| 76642 | <1% | 1,148 | $59K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,201 | $58K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 811 | $53K |
| 82962 | <1% | 8,026 | $52K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,647 | $52K |
| 76830 | Ultrasound, transvaginal | <1% | 1,869 | $50K |
| 86901 | <1% | 2,354 | $49K | |
| 93017 | <1% | 1,611 | $48K | |
| 77066 | Tomosynthesis, mammo | <1% | 889 | $46K |
| A9270 | Non-covered item or service | <1% | 12,079 | $44K |
| 72100 | <1% | 1,139 | $42K | |
| 93970 | <1% | 1,047 | $39K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,341 | $38K |
| 95811 | <1% | 128 | $36K | |
| 93971 | <1% | 1,324 | $35K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 286 | $34K |
| 86850 | <1% | 1,657 | $33K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 28,403 | $32K |
| 97162 | <1% | 929 | $32K | |
| 76770 | <1% | 424 | $32K | |
| 73562 | <1% | 1,729 | $30K | |
| 72040 | <1% | 846 | $30K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,279 | $29K |
| 73030 | <1% | 1,293 | $28K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 359 | $24K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 272 | $24K |
| 71045 | Radiologic examination, chest; single view | <1% | 12,186 | $24K |
| 81001 | <1% | 8,364 | $23K | |
| 87210 | <1% | 1,273 | $23K | |
| 73630 | <1% | 1,512 | $22K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 561 | $22K |
| 81002 | <1% | 920 | $21K | |
| 77080 | <1% | 575 | $20K | |
| 73610 | <1% | 856 | $20K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,976 | $19K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,549 | $19K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,687 | $18K |
| 84112 | <1% | 120 | $18K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,106 | $17K |
| 73130 | <1% | 733 | $15K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,272 | $14K |
| 76801 | <1% | 1,129 | $14K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,225 | $14K |
| 87400 | <1% | 1,520 | $13K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,405 | $13K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 337 | $13K |
| 81003 | <1% | 3,858 | $13K | |
| 87081 | <1% | 463 | $12K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 484 | $12K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,124 | $12K |
| 86900 | <1% | 2,079 | $11K | |
| 84484 | <1% | 11,758 | $11K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,459 | $11K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 161 | $11K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,836 | $11K |
| 81025 | <1% | 4,324 | $10K | |
| 73502 | <1% | 570 | $10K | |
| 72110 | <1% | 697 | $10K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,359 | $10K |
| 82731 | <1% | 57 | $9K | |
| 97161 | <1% | 169 | $9K | |
| 99152 | <1% | 619 | $9K | |
| 87631 | <1% | 102 | $9K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,873 | $8K |
| 84703 | <1% | 4,071 | $8K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,671 | $8K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 142 | $8K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 154 | $8K |
| 84702 | <1% | 1,701 | $7K | |
| 77065 | Tomosynthesis, mammo | <1% | 151 | $7K |
| 80061 | Lipid panel | <1% | 2,149 | $7K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 16 | $7K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 177 | $7K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,829 | $7K |
| 97163 | <1% | 130 | $7K | |
| 96376 | <1% | 2,764 | $7K | |
| 85610 | <1% | 4,675 | $7K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,350 | $6K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,505 | $6K |
| 87641 | <1% | 378 | $6K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,333 | $6K |
| 85730 | <1% | 3,275 | $6K | |
| 73110 | <1% | 237 | $6K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,246 | $5K |
| C1769 | Guide wire | <1% | 290 | $5K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 90 | $5K |
| 74240 | <1% | 57 | $5K | |
| 29581 | <1% | 47 | $5K | |
| 74018 | <1% | 278 | $5K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 23 | $5K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 105 | $5K |
| 83735 | <1% | 3,539 | $5K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,329 | $5K |
| 99153 | Mod sedat endo service >5yrs | <1% | 307 | $4K |
| 83880 | <1% | 3,157 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,208 | $4K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,161 | $4K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 229 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,668 | $3K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 28 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,467 | $3K |
| 72072 | <1% | 111 | $3K | |
| 71271 | <1% | 39 | $3K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,863 | $3K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 266 | $2K |
| 10060 | <1% | 12 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 43 | $2K |
| 94726 | <1% | 40 | $2K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 561 | $2K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 741 | $2K |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 266 | $2K |
| 97116 | <1% | 127 | $2K | |
| 70486 | <1% | 72 | $2K | |
| 83690 | <1% | 4,971 | $1K | |
| 80076 | <1% | 134 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,587 | $1K |
| 87077 | <1% | 417 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,392 | $1K |
| J1245 | Injection, dipyridamole, per 10 mg | <1% | 395 | $1K |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | <1% | 286 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,117 | $1K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 600 | $962.54 |
| 94060 | <1% | 43 | $951.51 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 13 | $886.32 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 605 | $884.52 |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 446 | $836.29 |
| 88341 | <1% | 16 | $826.77 | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 16 | $788.09 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 620 | $747.20 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 813 | $712.83 |
| 88342 | <1% | 37 | $691.14 | |
| 93880 | <1% | 45 | $680.97 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 179 | $643.48 |
| 85379 | <1% | 573 | $633.97 | |
| 83605 | <1% | 3,104 | $579.25 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 970 | $565.33 |
| 73080 | <1% | 15 | $501.31 | |
| 82565 | <1% | 232 | $480.99 | |
| J1750 | Injection, iron dextran, 50 mg | <1% | 16 | $393.71 |
| 84145 | <1% | 125 | $387.77 | |
| 87186 | <1% | 755 | $387.16 | |
| 80329 | <1% | 688 | $343.18 | |
| 87205 | <1% | 127 | $300.99 | |
| 87070 | <1% | 33 | $285.62 | |
| 72131 | <1% | 26 | $283.52 | |
| 82570 | <1% | 72 | $274.93 | |
| 87430 | <1% | 442 | $241.94 | |
| 86140 | <1% | 410 | $222.32 | |
| 84132 | <1% | 127 | $209.31 | |
| 80320 | <1% | 494 | $197.49 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 77 | $185.27 |
| 87040 | <1% | 822 | $162.88 | |
| 97166 | <1% | 76 | $137.57 | |
| 73590 | <1% | 26 | $136.99 | |
| 77062 | <1% | 90 | $125.48 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 191 | $124.68 |
| 86923 | <1% | 34 | $106.63 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 246 | $97.42 |
| 87634 | <1% | 156 | $86.93 | |
| 90715 | <1% | 29 | $84.08 | |
| 87807 | <1% | 12 | $81.95 | |
| 74021 | <1% | 67 | $74.10 | |
| 82803 | <1% | 19 | $40.96 | |
| 84550 | <1% | 62 | $38.41 | |
| 93325 | <1% | 23 | $29.02 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 33 | $26.50 |
| 82077 | <1% | 371 | $24.96 | |
| 94729 | <1% | 42 | $21.11 | |
| 82607 | <1% | 45 | $19.21 | |
| 82247 | <1% | 15 | $18.48 | |
| 84439 | <1% | 268 | $16.82 | |
| 82550 | <1% | 179 | $9.66 | |
| 85027 | <1% | 148 | $7.57 | |
| 87147 | <1% | 42 | $5.20 | |
| 82248 | <1% | 33 | $4.64 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 192 | $4.54 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 179 | $4.15 |
| 85014 | <1% | 45 | $3.96 | |
| 85652 | <1% | 174 | $3.44 | |
| 85018 | <1% | 47 | $1.98 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 44 | $0.50 |
| 90686 | <1% | 180 | $0.33 | |
| G0008 | Administration of influenza virus vaccine | <1% | 172 | $0.33 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 239 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 285 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 290 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 31 | $0.00 |
| J0280 | Injection, aminophyllin, up to 250 mg | 0% | 14 | $0.00 |
| 99406 | 0% | 25 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 30 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 65 | $0.00 |
| 83615 | 0% | 89 | $0.00 | |
| 97535 | Self-care/home management training, each 15 minutes | 0% | 39 | $0.00 |
| 36430 | 0% | 18 | $0.00 | |
| 88300 | 0% | 16 | $0.00 | |
| 84100 | 0% | 67 | $0.00 | |
| 82010 | 0% | 29 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 19 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 96 | $0.00 |
| 84156 | 0% | 44 | $0.00 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 17 | $0.00 |
| 36600 | 0% | 19 | $0.00 | |
| 77061 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROMINE, DONNIE (COO SVHC/PRESIDENT SVR)